TLC-ART featured on POZ.com

Prof. Ho’s Laboratory is featured on POZ.com, an influential print and online brand for people living with and affected by HIV/AIDS.

Highlighting pivotal developments in HIV treatment from 2023, the article echoes the findings of Perazzolo and colleagues at University of Washington TLC-ART program led by Prfo Ho. Their research introduces a groundbreaking long-acting injectable blend of tenofovir, lamivudine, and dolutegravir, proven effective for a month in primate studies. Leveraging cutting-edge nanoparticle technology, this formulation presents an accessible, possibly self-administered solution, marking a significant stride in enhancing HIV treatment and compliance, with particular promise for resource-limited settings.

https://www.poz.com/article/longerlasting-hiv-meds-horizon

HIV first-line TLD as one injectable lasting 1 month may be possible

TLC-ART can transform first-line 3 drugs TLD (tenofovir/lamivudine/tenofovir) as one long-acting injectable lasting 1 month in nonhuman primates

In a significant pharmaceutical breakthrough, researchers at our laboratory have successfully developed an innovative long-acting injectable version of the antiretroviral drug combination known as TLD, comprising tenofovir, lamivudine, and dolutegravir. This formulation, endorsed as the first-line treatment for HIV by the World Health Organization, employs advanced drug-combination nanoparticle technology. This technology significantly extends the duration of the drug’s presence in the bloodstream to up to one month with just a single injection. The groundbreaking results of this research, conducted on nonhuman primates for now, were recently published in the esteemed journal AIDS, garnering considerable attention and acclaim within the global AIDS research community.

The composition was made of generic and approved components, with public funding, and therefore costs should be limited, which can be of interest to low-mid income countries.

Additionally, leveraging the onboard tenofovir component, long-acting TLD holds the potential for coverage in people living with HIV and HBV.

NEWS:

AIDSmap

Spotlight

Research Article on AIDS

Prof Rodney Ho presented at IAS 2023 in Brisbane

Sept 12, 2023

Prof Ho presented TLC-ART work at IAS in Brisbane last July. TLC-ART has proposed the transformation of the short-acting HIV treatment, TLD (Tenofovir, Lamivudine, Dolutegravir), into a long-acting, single-injection formula that is stable in vivo and in nonhuman primates. This new formulation addresses “pill fatigue” and offers consistent treatment effects lasting over four weeks. This advancement paves the way for more efficient HIV treatments and a potential new standard in patient care.

IAS 2023 proceedings.

Contact: tlcart@uw.edu

New study in JIAS highlights U.S. patient preferences for long-acting HIV treatment

The study explores preferences for long-acting antiretroviral therapy (LA-ART) regimens among people with HIV (PWH) in the United States.

Summary of 2022-2023 TLC-ART Conferences and Presentations to date

2023 LEAP CROI 2023 Workshop in Seattle – Rodney Ho and Simone Perazzolo as plenary talks.

LEAP Logo

February 20, Seattle

The Long-Acting Extended Release Antiretroviral Research Resource Program (LEAP) virtually convened clinicians, investigators, developers, community advocacy groups, not-for-profit institutions, and regulatory authorities. Attendees shared their diverse perspectives and discussed updates, challenges, and future directions in the development of LA formulations. The meeting served as a forum to collectively advance the long-acting field. The Workshop consisted of two Plenary Sessions and four Focus Groups. Below, you’ll find links to video recordings and text summaries of the Plenary and Focus Group presentations.

TLC-ART Lab Update on HIV Therapies at LEAP Conference

Seattle, WA (Feb 12, 2022)–Earlier this month, Dr. Rodney Ho presented updates on the TLC-ART program’s Unitaid funded Global Long-Acting Drug Development (GLAD) Project at the LEAP (Lon-Acting/Extended Release Antiretroviral Research Resource Program) annual meeting.

As part of this meeting, Dr. Ho lectured on the progress of the GLAD project in transforming the current best-of-class oral daily 3-drug pill (Tenofovir, Lamivudine, and Dolutegravir) into a long-acting injectable therapy that can improve patient adherence and provide a higher quality of life for People Living with HIV (PLHIV) globally.

TLC-ART and MPP sign a licence agreement for a long-acting injectable candidate for HIV

TLC-ART program signs a license agreement with MPP to develop long-acting HIV therapeutics.

FDA Approves TLC Alumnus John Hoekman’s Migraine-Treating Nasal Spray

FDA Approves TLC Alumnus Dr. Hoekman’s Migraine Therapy.

TLC-ART Director Dr. Rodney JY Ho Named to National Academy of Inventors

TLC-ART is honored to announce that Director and UWSOP Professor of Pharmaceutics Rodney JY Ho has been elected to the rank of NAI Fellow by the 2020 National Academy of Inventors Fellows Selection Committee and Board of Directors.

“Dr. Ho has demonstrated a highly prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development, and the welfare of society,” said NAI President Paul R. Sanberg. “Our sincere congratulations on this well-deserved recognition of his accomplishments, and it is an honor to welcome him as a Fellow. I look forward to working with Dr. Ho in support of NAI’s mission to promote the importance of innovation and celebration of academic invention.”

Dr. Ho Talks Pfizer and COVID-19 Vaccine Distribution with KOMO News 4

Dr. Rodney Ho, Executive Director of WE-REACH, discussed the Pfizer COVID-19 vaccine and the challenges of distributing a treatment that requires -80 degree Celsius freezer storage with KOMO News last Friday. While “it is logistically challenging,” Dr. Ho believes that “we have prepared the best as we can.”

For the full story, follow the link to KOMO News 4.